Cronos Group Inc.
The stored financial sources have not been reconciled. Differences can involve reporting periods, currencies, continuing operations or income attributable to different owners. A model rating is withheld until the figures are compared on a consistent basis.
CRON · Price history
Price at last available close
$3.34
−$0.07 (-2.05%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Cronos Group Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Cronos Group Inc. is a company primarily focused on cannabinoids. In the United States, it develops, promotes, and supplies hemp-derived wellness and beauty products under the Lord Jones and Happy Dance brands, reaching consumers through online sales, traditional retail outlets, and partnerships within the hospitality sector. Beyond hemp, the company also engages in the cultivation, production, and commercialization of cannabis and its related extracts for both therapeutic and recreational consumption.
How they make money
Cronos Group Inc. is a global cannabinoid company that generates revenue through the cultivation, production, and marketing of cannabis and cannabis-derived products. The company sells its products primarily through Canadian provincial cannabis control authorities and private retailers, as well as through international medical cannabis markets in countries including Israel, Germany, and Australia.
Products & services
The company produces and distributes cannabis products including dried flower, pre-rolls, edibles, vaporizers, and concentrates under various brand names.
Brands & revenue mix
Core brand for adult-use cannabis products including dried flower and vapes.
Separate brand revenue is not available in this research.Source
Brand focused on medical cannabis markets.
Separate brand revenue is not available in this research.Source
Lifestyle and wellness cannabis brand.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer types
Customer concentration
As of the period ended December 31, 2025, the company relies on provincial cannabis control authorities in Canada as primary distribution channels, which represents a significant concentration of its revenue base.
Suppliers, materials & equipment
- Cannabis cultivators and processors — The company maintains supply agreements with various third-party suppliers for dried flower and other cannabis products to supplement its own production.Source
Strengths
- Strong balance sheet with significant cash and cash equivalentsSource
Company-specific research
Questions worth answering for CRON
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can CRON maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is CRON's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is CRON likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is CRON's valuation discount tied to a temporary concern or to a longer-term business risk?
- •What does the current financial source inconsistency warning mean for the reliability or interpretation of CRON's score?
Essential Investment Snapshot
Market Cap
$1.23B
EPS
$0.18
52-Week High
$3.61
52-Week Low
$2.28
Beta
1.20
Analyst Target
$2.90
Shares Outstanding
385.3M
Total Debt
$1.3M
Dividend
No current dividend
Liquidation Value / Share
$2.90
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for CRON
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
M&A headline · Oct 15, 2026
Cronos Completes Acquisition of CanAdelaar, Europe's Largest Adult-Use Cannabis Company — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireM&A headline · Oct 5, 2026
Cronos Group Inc. $CRON Shares Newly Acquired by Bank of America Corp DE — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on CRON.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Strong balance sheet with significant cash and cash equivalents.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - Specialty & Generic industry.
- −Regulatory risks associated with the evolving cannabis legal framework.
- −Dependence on third-party supply agreements and operational risks at production facilities.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
UndervaluedCurrent Price
$3.35
Model Intrinsic Value
$6.98
Difference
−$3.64
-52.1% vs IV
Margin of Safety
52.1%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $225.2M | $149.2M | $117.6M | $87.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $143.8M | $87.5M | $92.4M | $75.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $81.4M | $61.7M | $25.2M | $11.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $5.3M | $4.4M | $4.2M | $5.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $67.0M | $63.8M | $76.8M | $80.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $68.8M | $79.5M | $101.7M | $96.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $11.4M | -$3.4M | -$50.2M | -$71.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $12.6M | -$17.8M | -$76.5M | -$84.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $68.2M | -$17.4M | $36.6M | -$73.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$10.8M | -$14.4M | -$3.4M | -$3.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $69.8M | -$9.6M | $41.1M | -$74.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $0.18 | $-0.03 | $0.11 | $-0.19 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 385M | 385M | 382M | 381M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 385M | 385M | 386M | 381M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$53.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.08
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-35.6%
Cash Change
-41.2%
Margin Change
+179.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 58.4%. EPS declined 183.3%. Cash declined 41.2%. Total debt declined 35.6%. Net income margin improved by 179.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
7 historical recordsHistorical Score Chart
3 of 7 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericNews
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Cronos Completes Acquisition of CanAdelaar, Europe's Largest Adult-Use Cannabis Company
Fan-Favorite and Limited-Edition Spinach® Green Apple-Flavored Products are Returning for the Fall Season
CRON Stock Rises 17% in Three Months: Time to Buy the Dip or Cash Out?
Rumor Mill · CRON
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial